Unlocking New Potential For Biotechnology.

We focus on pre-seed biopharma platforms, tools and diagnostics companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.

Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit via high-value M&A opportunities or secondaries–maximizing both investor returns and industry impact.

We believe that early stage biopharma platforms, tools and diagnostics are on the cusp of major growth (7-11% CAGR to 2030 according to Grandview Research), due to rapid advances in omics data and agentic AI.

Historically, the sector has been underfunded relative to therapeutics but recent VC rounds and exits in 2024 and early 2025 are showing an uptick in activity, as documented in Pitchbook's Q4 2024 report.